current
approv
antivir
therapi
treatment
ebola
viru
diseas
discov
readili
avail
approv
drug
rapidli
repurpos
treatment
ebola
viru
infect
screen
fdaapprov
drug
identifi
glycopeptid
antibiot
teicoplanin
inhibit
ebola
pseudoviru
infect
block
viru
entri
low
micromolar
rang
teicoplanin
could
evalu
incorpor
ongo
clinic
studi
ebola
viru
ebov
member
filovirida
envelop
filament
nonseg
negativesens
rna
viru
caus
deadli
ebola
viru
diseas
evd
feldmann
geisbert
februari
largest
known
evd
outbreak
start
guinea
virolog
investig
identifi
zair
ebola
viru
zebov
caus
agent
baiz
et
al
juli
total
case
death
report
http
wwwwhointcsrdiseaseebolasituationreportsen
result
fatal
rate
date
antivir
therapeut
approv
treat
patient
evd
treatment
remain
limit
support
care
therefor
urgent
need
discoveri
develop
antivir
agent
ebov
infect
ebov
biosafeti
level
pathogen
work
infecti
ebov
restrict
laboratori
henc
biolog
ebov
infect
remain
rel
poorli
understood
hamper
vaccin
drug
develop
order
overcom
limit
surrog
system
allow
model
viru
life
cycl
condit
develop
hoenen
feldmann
pseudoparticl
express
ebov
glycoprotein
gp
commonli
use
tool
studi
ebov
entri
identif
ebov
entri
inhibitor
viru
attach
entri
offer
numer
target
antivir
therapi
enfuvirtid
peptid
inhibitor
viru
entri
success
use
treatment
infect
altmey
set
screen
approv
drug
identif
potenti
therapeut
option
evd
drug
repurpos
valid
approach
sever
exist
drug
proven
effect
new
indic
ashburn
thor
chong
sullivan
perform
screen
fdaapprov
drug
use
ebov
zair
strain
gphiv
core
pseudoviru
contain
firefli
luciferas
fluc
report
gene
design
pebov
kindli
provid
prof
paul
zhou
institut
pasteur
shanghai
identifi
new
inhibitor
fig
show
scheme
primari
screen
hit
select
process
briefli
vero
cell
cell
ml
dmem
seed
well
white
plate
corn
costar
incub
c
co
h
prior
infect
five
microlit
test
compound
final
concentr
mm
dilut
assay
media
final
dmso
concentr
ad
plate
one
compound
per
well
cell
control
pebov
infect
control
well
dmso
alon
ad
within
min
compound
addit
ml
pebov
ad
well
cell
control
well
ml
assay
medium
ad
final
assay
volum
mlwell
plate
incub
c
co
h
allow
equilibr
room
temperatur
min
afterward
ml
brightglo
promega
reagent
ad
plate
well
plate
incub
room
temperatur
screen
singl
dose
mm
activ
pebov
compound
activ
inhibit
pebov
subsequ
screen
vsv
pseudoviru
pvsv
lead
compound
select
activ
pebov
doserespons
analysi
confirm
two
compound
teicoplanin
toremiphen
met
select
criteria
ec
mm
si
pebov
pebovpvsv
b
activ
teicoplanin
pebov
pvsv
threefold
serial
dilut
teicoplanin
ad
vero
cell
h
incub
rel
infect
analyz
measur
luciferas
present
percentag
luciferas
deriv
compoundtr
cell
compar
mocktreat
cell
cytotox
also
examin
incub
vero
cell
indic
concentr
teicoplanin
present
percentag
luminesc
deriv
compoundtr
cell
compar
mocktreat
cell
medium
c
effect
human
serum
albumin
hsa
antipebov
activ
teicoplanin
activ
teicoplanin
pebov
evalu
presenc
indic
concentr
hsa
ec
calcul
use
prism
nonlinear
regress
zhang
et
al
averag
signaltobackground
sb
ratio
signaltonois
sn
ratio
respect
total
compound
greater
inhibit
pebov
infect
identifi
secondari
screen
vsv
ghiv
core
pseudoviru
contain
fluc
report
gene
design
pvsv
also
provid
prof
paul
zhou
assay
condit
compound
less
inhibit
pvsv
infect
consid
primari
hit
yield
hit
rate
compound
includ
sever
previous
report
inhibitor
estrogen
receptor
modul
tamoxifen
johansen
et
al
kouznetsova
et
al
clomiphen
johansen
et
al
toremiphen
johansen
et
al
kouznetsova
et
al
madrid
et
al
histamin
antagonist
clemastin
kouznetsova
et
al
johansen
et
al
antidepress
paroxetin
johansen
et
al
madrid
et
al
ion
channel
inhibitor
amiodaron
gehr
et
al
salata
et
al
glycopeptid
antibiot
teicoplanin
johansen
et
al
valid
activ
primari
hit
compound
repurchas
dri
powder
dissolv
dmso
except
teicoplanin
dissolv
medium
eightpoint
doserespons
analysi
perform
duplic
three
assay
includ
assay
primari
screen
pebov
pvsv
cytotox
assay
cytotox
compound
assess
parallel
without
addit
pseudoviru
measur
celltiterglo
promega
reagent
determin
concentr
result
inhibit
cell
viabil
cc
compound
select
index
si
calcul
si
cc
ec
ratio
ec
pvsv
ec
pebov
pebovpvsv
use
rule
compound
inhibit
fluc
express
hiv
replic
chemic
structur
cc
ec
si
valu
pebovpvsv
compound
list
tabl
select
criteria
compound
character
requir
compound
ec
mm
si
pebov
pebovpvsv
two
compound
teicoplanin
toremiphen
met
criteria
teicoplanin
select
addit
character
previou
studi
shown
toremiphen
interfer
step
late
viral
entri
like
affect
trigger
fusion
johansen
et
al
teicoplanin
glycopeptid
antibiot
use
treatment
gramposit
bacteri
infect
pea
et
al
sancar
et
al
effect
inhibit
pebov
dosedepend
manner
ec
mm
ec
mm
si
greater
fig
mm
teicoplanin
complet
inhibit
pebov
infect
without
cytotox
slightli
less
inhibit
pvsv
infect
suggest
select
inhibitor
pebov
sinc
teicoplanin
highli
bound
plasma
protein
wilson
yagasaki
et
al
evalu
effect
human
serum
albumin
hsa
antipebov
activ
teicoplanin
presenc
hsa
doserespons
curv
shift
toward
higher
ec
valu
concentr
increas
fig
fold
shift
ec
presenc
hsa
respect
albumin
present
human
serum
concentr
rang
mgml
ec
teicoplanin
pebov
human
rang
mm
mgl
recent
johansen
cowork
johansen
et
al
also
show
teicoplanin
activ
egfpebov
vitro
howev
protect
observ
ebovinfect
mice
treatment
teicoplanin
dose
mgkg
bodi
weight
daili
day
specul
failur
due
therapeut
concentr
teicoplanin
achiev
perhap
higher
dose
eg
daili
dose
mgkg
shown
safe
effect
decreas
bacteremia
domenech
et
al
may
lead
signific
surviv
benefit
maintain
serum
concentr
teicoplanin
ec
patient
infect
ebov
key
success
outcom
clinic
set
given
trough
plasma
concentr
cmin
mgl
estim
ec
pebov
human
achiev
sampl
toxic
seen
cmin
reach
mgl
tobin
et
al
teicoplanin
may
potenti
treatment
evd
nevertheless
new
dosag
guidelin
develop
ensur
optim
drug
exposur
major
patient
may
evd
moreov
vancomycin
also
use
treatment
gramposit
bacteri
infect
structur
relat
teicoplanin
show
inhibit
mm
fig
suggest
structur
differ
teicoplanin
vancomycin
eg
long
fatti
acid
chain
attach
teicoplanin
absent
vancomycin
differ
structur
aglycon
crucial
antipebov
activ
ebov
bind
target
cell
interact
either
glycan
gp
ctype
lectin
clec
virionassoci
phosphatidylserin
phosphatidylserin
receptor
initi
entri
mollertank
mauri
intern
via
macropinocytosi
traffic
endosom
nanbo
et
al
saeed
et
al
gp
cleav
host
proteas
cathepsin
chandran
et
al
bind
cleav
gp
endosom
membran
protein
niemannpick
trigger
fusion
facilit
releas
viral
nucleoprotein
cytoplasm
prior
initi
viru
replic
carett
et
al
cote
et
al
determin
stage
viral
entri
pathway
teicoplanin
inhibit
infect
perform
preand
postattach
assay
teicoplanin
incub
pebov
h
pebov
bind
monolay
vero
cell
infect
measur
firefli
luciferas
assay
shown
fig
teicoplanin
effici
inhibit
infect
premix
pebov
ad
infect
howev
inhibit
detect
ad
viru
adsorpt
cell
surfac
indic
teicoplanin
block
viral
entri
teicoplanin
aglycon
deriv
report
inhibit
subgenom
hcv
replic
obeid
et
al
took
advantag
ebov
minigenom
system
scheme
fig
construct
synthes
generay
biotech
ltd
shanghai
china
base
sequenc
genbank
access
number
test
whether
teicoplanin
inhibit
ebov
replic
bsr
cell
stabli
express
rna
polymeras
kindli
provid
prof
dr
karlklau
conzelmann
maxvonpettenkof
institut
germani
seed
cellswel
plate
corn
costar
h
advanc
cell
transfect
plasmid
encod
ebov
np
ng
ng
ng
l
ng
protein
minigenom
ng
contain
fluc
report
gene
use
lipofectamin
invitrogen
plasmid
ng
encod
renilla
luciferas
cotransfect
intern
control
normal
transfect
effici
transfect
without
plasmid
express
l
protein
serv
neg
control
teicoplanin
ad
transfect
left
incub
cell
h
transfect
cell
lyse
luciferas
lysi
buffer
firefli
luciferas
well
renilla
luciferas
signal
measur
well
dualluciferas
report
assay
system
promega
contrast
inhibitori
effect
subgenom
hcv
replic
teicoplanin
inhibit
replic
ebov
minigenom
test
concentr
fig
observ
togeth
result
preand
postattach
assay
suggest
mechan
inhibit
pebov
teicoplanin
block
viru
entri
teicoplanin
deriv
report
inhibit
sever
virus
hiv
balzarini
et
al
preobrazhenskaya
olsufyeva
influenza
bereczki
et
al
hcv
maieron
kerschner
obeid
et
al
dengu
viru
flavivirus
de
burghgraev
et
al
coronavirus
includ
sarscov
fipv
balzarini
et
al
virus
envelop
virus
question
whether
teicoplanin
inhibit
wide
varieti
envelop
virus
nonenvelop
virus
evalu
activ
teicoplanin
anoth
envelop
viru
human
respiratori
syncyti
viru
hrsv
strain
long
three
nonenvelop
virus
includ
enteroviru
strain
coxsackieviru
strain
polioviru
strain
sabin
interestingli
teicoplanin
reduc
viral
titer
hrsv
mm
respect
fig
howev
inhibit
observ
test
concentr
fig
suggest
teicoplanin
probabl
target
common
compon
among
envelop
virus
target
cell
conclus
identifi
glycopeptid
antibiot
teicoplanin
inhibitor
ebov
pseudoviru
cell
cultur
block
wash
remov
unbound
pebov
compound
fresh
medium
ad
incub
c
h
preattach
assay
pebov
incub
mm
teicoplanin
c
h
prior
addit
cell
viruscompound
mixtur
incub
cell
c
h
cell
wash
medium
incub
c
h
postattach
assay
vero
cell
prechil
c
pebov
ad
cell
viru
adsorpt
allow
h
c
cell
wash
three
time
cold
medium
remov
unbound
viru
mm
teicoplanin
ad
h
c
cell
wash
incub
c
h
data
averag
quadrupl
well
two
independ
experi
error
bar
repres
standard
deviat
mean
statist
signific
treat
control
group
analyz
ttest
ns
signific
p
p
p
b
minigenom
assay
teicoplanin
upper
schemat
diagram
ebola
viru
zair
strain
minigenom
use
studi
viral
gene
remov
replac
firefli
luciferas
fluc
report
gene
nontranscrib
leader
trailer
region
well
noncod
region
upstream
downstream
np
gene
retain
minigenom
mg
flank
rna
polymeras
promot
ribozym
hdvr
minigenom
replic
transcrib
np
l
provid
tran
express
plasmid
lower
bsr
cell
transfect
minigenom
express
plasmid
rnp
protein
np
l
h
incub
transfect
complex
cell
treat
mm
mm
mm
teicoplanin
firefli
renilla
luciferas
activ
measur
h
posttransfect
cell
transfect
without
l
plasmid
set
background
effect
teicoplanin
present
percentag
firefli
luciferas
normal
renilla
luciferas
deriv
compoundtr
cell
compar
mocktreat
cell
data
present
obtain
two
independ
experi
error
bar
repres
standard
deviat
two
independ
experi
entri
base
long
histori
clinic
use
achiev
high
enough
human
exposur
teicoplanin
potenti
rapidli
advanc
clinic
set
moreov
teicoplanin
also
provid
good
tool
gain
novel
insight
entri
process
ebov
fig
effect
teicoplanin
hrsv
left
cytotox
teicoplanin
cell
assess
eightpoint
doserespons
right
cell
infect
hrsv
subtyp
strain
long
moi
treat
teicoplanin
indic
concentr
supernat
collect
h
postinfect
viral
titer
determin
immunostain
assay
b
cytotox
teicoplanin
rd
cell
assess
eightpoint
doserespons
cell
infect
moi
moi
treat
teicoplanin
indic
concentr
supernat
collect
h
postinfect
viral
titer
determin
plaqu
assay
b
data
present
obtain
two
independ
experi
error
bar
repres
standard
deviat
two
independ
experi
statist
signific
treat
control
group
analyz
ttest
ns
signific
p
p
